期刊文献+

Combined effect of atorvastatin and probucol on plasma cystatin C levels and severity of coronary lesion in patients with borderline coronary lesion 被引量:11

Combined effect of atorvastatin and probucol on plasma cystatin C levels and severity of coronary lesion in patients with borderline coronary lesion
原文传递
导出
摘要 Background The plasma cystatin C concentration (PcyC) has been demonstrated to have prognostic value in acute coronary syndrome, but the study of PcyC in patients with borderline coronary lesions is limited. Moreover, the effects of atorvastatin and probucol on PcyC and the severity of coronary lesions are unknown. This study was to evaluate the effects of the combination of atorvastatin and probucol on PcyC and severity of coronary lesion in patients with borderline coronary lesions. Methods One hundred and thirty consecutive patients with borderline coronary lesions (40% to 60% isolated single stenosis assessed by quantitative coronary angiography) were enrolled into the borderline coronary lesion (BCL) group, and one hundred and thirty-six subjects without coronary lesions comprised the controls (CTR). The subjects in the BCL group were randomized into routine treatment (RTT, n=60), and combined treatment with atorvastatin 20 mg plus probucol 1.0 g daily added to routine medication (CBT, n=70), both groups were treated for 6 months continuously. The levels of PcyC, high-sensitive C-reactive protein (hs-CRP), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG) were determined. One hundred and four subjects in the BCL group were rechecked by coronary angiography. Results PcyC levels were significantly higher in the BCL group than in the CTR group; (2003.26+825.73) ng/ml vs. (1897.83+664.46) ng/ml (P 〈0.01). Compared with patients in the RTT group, the levels of PcyC, TC, LDL-C, TG and hs-CRP were significantly lower in the CBT group (P 〈0.05). Moreover, there was a trend towards a slight decrease in the RTT patients, (54.38+10.67)% vs. (50.29+9.89)% (P 〉0.05), and a significant decrease in the CBT patients, (53.65+9.48%) vs. (40.38+12.93)% (P 〈0.05), in the mean percent stenosis of borderline coronary lesions before and after six months of treatment. Conclusions Cystatin C played an important role in with the severity of coronary lesions. The combination the treatment of choice. the development of coronary artery disease, and was associated of atorvastatin and probucol decreased PcyC levels, and could be Background The plasma cystatin C concentration (PcyC) has been demonstrated to have prognostic value in acute coronary syndrome, but the study of PcyC in patients with borderline coronary lesions is limited. Moreover, the effects of atorvastatin and probucol on PcyC and the severity of coronary lesions are unknown. This study was to evaluate the effects of the combination of atorvastatin and probucol on PcyC and severity of coronary lesion in patients with borderline coronary lesions. Methods One hundred and thirty consecutive patients with borderline coronary lesions (40% to 60% isolated single stenosis assessed by quantitative coronary angiography) were enrolled into the borderline coronary lesion (BCL) group, and one hundred and thirty-six subjects without coronary lesions comprised the controls (CTR). The subjects in the BCL group were randomized into routine treatment (RTT, n=60), and combined treatment with atorvastatin 20 mg plus probucol 1.0 g daily added to routine medication (CBT, n=70), both groups were treated for 6 months continuously. The levels of PcyC, high-sensitive C-reactive protein (hs-CRP), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG) were determined. One hundred and four subjects in the BCL group were rechecked by coronary angiography. Results PcyC levels were significantly higher in the BCL group than in the CTR group; (2003.26+825.73) ng/ml vs. (1897.83+664.46) ng/ml (P 〈0.01). Compared with patients in the RTT group, the levels of PcyC, TC, LDL-C, TG and hs-CRP were significantly lower in the CBT group (P 〈0.05). Moreover, there was a trend towards a slight decrease in the RTT patients, (54.38+10.67)% vs. (50.29+9.89)% (P 〉0.05), and a significant decrease in the CBT patients, (53.65+9.48%) vs. (40.38+12.93)% (P 〈0.05), in the mean percent stenosis of borderline coronary lesions before and after six months of treatment. Conclusions Cystatin C played an important role in with the severity of coronary lesions. The combination the treatment of choice. the development of coronary artery disease, and was associated of atorvastatin and probucol decreased PcyC levels, and could be
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2012年第14期2472-2476,共5页 中华医学杂志(英文版)
关键词 cystatin C coronary artery disease borderline coronary lesion cystatin C coronary artery disease," borderline coronary lesion
  • 相关文献

参考文献4

二级参考文献70

  • 1蒋兴亮,周京国,唐中,张均.冠心病患者对氧磷酯酶1活性与氧化型低密度脂蛋白的关系[J].中华老年心脑血管病杂志,2004,6(5):305-307. 被引量:8
  • 2冯建芳,汪淑荣,李平,赵一鸣,孙诠,师树古,陈明哲.急性心肌梗塞病人血清巯基蛋白酶抑制肽C的变化[J].基础医学与临床,1995,15(4):45-47. 被引量:20
  • 3Tao CW,Yung HC,Hsin BL.Carvedilol,a pharmacolngical antioxidant,inhibits neointimal matrix metaUaproteinaso-2 and -9 in experimental atherosclerosis.Free Bad Biolo Med,2007,43:1508-1522.
  • 4Zorina SG,Kazubiko A,Denis G,et al.N-Acetyl-cysteine decrease the matrix-degrading capacity of macrophage derive foam cell,Circulation,1998,97:2445-2453.
  • 5Derosa G,D'Angelo A,Scalise F,et al.Comparison between metallopmteinases-2 and -9 in healthy subjects,diabetics,and subjects with acute coronary syndrome.Heart Vessels,2007,22:361-370.
  • 6Sawayama Y,Tatsukawa M,Kikuchi K,et al.Effect on carotid atherosclerosis of probucol plus levofloxacin for chlamydia pneumoniae infection.J Infect Chem,2007,13:92-98.
  • 7Iqbal M,Oknzaki Y,Okada S,et al.Probueol modulates iron nitrilotriacetate (Fe-NTA)-dependent renal carcinogenesis and hyperprollferative response:diminution of oxidative stress.Mol Cell Biochem.2007,304:61-69.
  • 8Yoshikawa T,Mitani K,Kotosai K,et al.Antiatherogenic effects of cilostazol and probucol alone,and in combination in low density lipoprotein receptor-deficient mice fed with a high fat diet.Horm Metab Res,2008,40:473-478.
  • 9Tanous,D,Hime N,Stocker R,et al.Roland anti-atherosclerotic and anti-diabetic properties of probueol and related compounds.Redox Rep,2008,13:48-59.
  • 10Kita T,Nagano Y,Yokode M,Ishi K,Kume N,Ooshima A,et al.Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit,an animal model for familial hypercholesterolemia.Proc Natl Acad Sci USA 1987; 84:5928-5931.

共引文献161

同被引文献47

引证文献11

二级引证文献78

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部